Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary obstruction. Its main purpose was to report mortality and stent failure at long term, which remained unknown. 

COMPARE TAVI: Resultados al año de un estudio aleatorizado que compara dos válvulas balón expandibles

Primary end point was long term mortality, while secondary end point was stent failure. This was a multicenter study including patients from 35 centers distributed along three continents. Patients with all kinds of stents or valves participated, in contexts of native aortic stenosis or valve-in-valve procedures, and with traditional or orthotropic chimney stenting.

Participant mean age was 80.9 years. 30.7% of the total procedures were done in native valves, 64.6% were TAV-in-SAV, and 4.7% TAV-in-TAV. Most cases (72.5%), received the classical chimney technique with a stent positioned as protection. 

Patients with established coronary artery obstruction presented significantly more adverse events, mainly death and cardiogenic shock, vs. those treated with coronary obstruction prevention strategies. 

Read also: CCANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx.

The absence of coronary protection was significantly associated with a combined end point of hospital mortality, acute myocardial infarction and cardiogenic shock (OR 8.36; CI95% 3.84-18.18; p≤0.001).

Among mortality predictors at 30 days, the most significant were the presence of established CAD (OR 10.02; p≤0.001) and lack of coronary protection (OR 7.11; p=0.002). On the other hand, long term mortality predictors were stage ≥2 kidney failure (OR 2.32; p=0.039) and access other than femoral. There were no predictors of stent failure. 

Read also: TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation.

Chimney stent failure was low (4%), with no significant differences in events according to coronary prevention strategy. At midterm follow-up, global mortality reached 22.4%.

Presented by Paolo Alberto del Sole at Top Late-Breaking Trials, PCR London Valves, November 24, 2024, London, GB.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

IVUS Assessment in Patients at High Risk of Coronary Occlusion After TAVI: Results from the ICARO Study

Courtesy of Dr. Juan Manuel Pérez. Acute coronary obstruction (ACO) is a rare but potentially fatal complication following transcatheter aortic valve implantation (TAVI), particularly in...

Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing...

Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes

Tricuspid regurgitation (TR) has been associated with increased mortality and functional deterioration. Even though the current guidelines recommend tricuspid valve surgery, supporting evidence is...

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

Researchers analyzed a total of 1062 patients who underwent transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation (TR). Risk was classified using the TRI-SCORE: low (0–3...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

iVAC2L: New Contribution to Ventricular Assist Devices in High Risk PCIs

The use of mechanical circulatory support (MCS) is on the rise, or increasingly necessary, seeing as high risk percutaneous coronary interventions (HR-PCIs) with severe...